Dedifferentiated Liposarcoma

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas [Phase 3]

  This Phase 3 trial is evaluating whether adding immunotherapy to chemotherapy improves outcomes versus chemotherapy alone in patients with a…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial is evaluating adding abemaciclib to gemcitabine for soft tissue sarcoma; recruitment is ongoing.

• CLINICAL_TRIALS research · 2026-03-13
  Clinical Trial Update: A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma [Phase 1, Phase 2]

  This update reports on a Phase 1/2 clinical trial evaluating the MEK inhibitor mirdametinib in combination with palbociclib for liposarcoma,…

• CLINICAL_TRIALS research · 2026-02-25
  Clinical Trial Update: Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

  Clinical trial update describing precision medicine approaches for neoadjuvant therapy in high‑risk sarcoma patients; currently recruiting.

• CLINICAL_TRIALS research · 2026-02-04
  Clinical Trial Update: A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma [Phase 1]

  This Phase 1 study evaluates LN-144 or LN-145 in people with advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2026-01-26
  Clinical Trial Update: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma [Phase 2]

  Phase 2 study evaluating cemiplimab in combination with palbociclib for advanced or unresectable dedifferentiated liposarcoma; the trial is …

• CLINICAL_TRIALS research · 2025-10-20
  Clinical Trial Update: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma [Phase 2]

  A Phase 2 study evaluating the combination of Etrumadenant and Zimberelimab in Dedifferentiated liposarcoma; the trial is currently active b…

• CLINICAL_TRIALS research · 2025-09-05
  Clinical Trial Update: A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors [Phase 1]

  Phase 1 first-in-human trial evaluating OKN4395 in combination with pembrolizumab in patients with solid tumors is currently recruiting. The…

• CLINICAL_TRIALS research · 2025-08-28
  Clinical Trial Update: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) [Phase 2]

  This document reports a Phase 2 open-label trial (PERELI) investigating the combination of pemigatinib and retifanlimab in advanced dediffer…

• CLINICAL_TRIALS research · 2024-12-06
  Clinical Trial Update: SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma [Phase 3]

  A Clinical Trial Update for the Phase 3 SARC041 study comparing abemaciclib to placebo in patients with advanced dedifferentiated liposarcom…

• CLINICAL_TRIALS research · 2024-11-19
  Clinical Trial Update: First-line Treatment of Advanced/unresectable DDLPS [Phase 2]

  This clinical trial update outlines a Phase 2 first-line treatment study for advanced or unresectable dedifferentiated liposarcoma (DDLPS) a…